MERUS N.V. EO -09 Market Cap ($6.11 Billion)
Market Cap & Net Worth: MERUS N.V. EO -09 (2GH)
MERUS N.V. EO -09 market cap. MERUS N.V. EO -09 (F:2GH) has a market capitalization of $6.11 Billion (€5.23 Billion) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #3032 globally and #600 in its home market, demonstrating a -0.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MERUS N.V. EO -09's stock price €79.00 by its total outstanding shares 75847175 (75.85 Million).
MERUS N.V. EO -09 Market Cap History (2018–2025)
MERUS N.V. EO -09 market cap history from 2018 to 2025. Data shows growth from $970.44 Million to $7.01 Billion (25.17% CAGR). Check MERUS N.V. EO -09 (2GH) share price today for real-time trading data and today's change.
MERUS N.V. EO -09 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MERUS N.V. EO -09's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2GH by Market Capitalization
Companies near MERUS N.V. EO -09 in the global market cap rankings as of November 4, 2026.
Key companies related to MERUS N.V. EO -09 by market ranking:
- LI NING CO.LTD UNS.ADR/25 (F:LNL): Ranked #3023 globally with a market cap of $6.14 Billion USD ( €5.25 Billion EUR).
- Silergy Corp (TW:6415): Ranked #3024 globally with a market cap of $6.14 Billion USD ( NT$194.82 Billion TWD).
- Zhongtai Securities Co Ltd (SHG:600918): Ranked #3033 globally with a market cap of $6.11 Billion USD ( CN¥41.73 Billion CNY).
- Henan Shijia Photons Technology Co Ltd (SHG:688313): Ranked #3034 globally with a market cap of $6.10 Billion USD ( CN¥41.71 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #3023 | LI NING CO.LTD UNS.ADR/25 | F:LNL | $6.14 Billion | €51.00 |
| #3024 | Silergy Corp | TW:6415 | $6.14 Billion | NT$501.00 |
| #3033 | Zhongtai Securities Co Ltd | SHG:600918 | $6.11 Billion | CN¥5.27 |
| #3034 | Henan Shijia Photons Technology Co Ltd | SHG:688313 | $6.10 Billion | CN¥90.90 |
Market Capitalization of MERUS N.V. EO -09 (2018–2025)
Market capitalization of MERUS N.V. EO -09 from 2018 to today. Between 2018 and today, MERUS N.V. EO -09's market cap moved from $970.44 Million to $ 7.01 Billion, with a yearly change of 25.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €7.01 Billion | +99.49% |
| 2024 | €3.51 Billion | +58.40% |
| 2023 | €2.22 Billion | +73.61% |
| 2022 | €1.28 Billion | -48.57% |
| 2021 | €2.48 Billion | +100.00% |
| 2020 | €1.24 Billion | +3.70% |
| 2019 | €1.20 Billion | +23.36% |
| 2018 | €970.44 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of MERUS N.V. EO -09 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.11 Billion USD |
| MoneyControl | $6.11 Billion USD |
| MarketWatch | $6.11 Billion USD |
| marketcap.company | $6.11 Billion USD |
| Reuters | $6.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MERUS N.V. EO -09
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more